DE60030229D1 - Katalytische Domäne der menschlichen Effektor Zellzyklus Kontrollpunkt-proteinkinase Chk1, Materialien und Verfahren zur Identifizierung von Inhibitoren davon - Google Patents

Katalytische Domäne der menschlichen Effektor Zellzyklus Kontrollpunkt-proteinkinase Chk1, Materialien und Verfahren zur Identifizierung von Inhibitoren davon

Info

Publication number
DE60030229D1
DE60030229D1 DE60030229T DE60030229T DE60030229D1 DE 60030229 D1 DE60030229 D1 DE 60030229D1 DE 60030229 T DE60030229 T DE 60030229T DE 60030229 T DE60030229 T DE 60030229T DE 60030229 D1 DE60030229 D1 DE 60030229D1
Authority
DE
Germany
Prior art keywords
hchk1
protein kinase
catalytic domain
checkpoint protein
human effector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60030229T
Other languages
English (en)
Other versions
DE60030229T2 (de
Inventor
Ping Chen
Keck Kan
Chun Luo
Stephen Margosiak
Patrick O'connor
Anna Tempczyk-Russel
Binh Nguyen
Jay Chand Sarup
Smita Gaur
Mark Brian Anderson
Ya-Li Deng
Karen Lundgren
James Register
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agouron Pharmaceuticals LLC
Original Assignee
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals LLC filed Critical Agouron Pharmaceuticals LLC
Application granted granted Critical
Publication of DE60030229D1 publication Critical patent/DE60030229D1/de
Publication of DE60030229T2 publication Critical patent/DE60030229T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE60030229T 1999-11-01 2000-10-31 Katalytische Domäne der menschlichen Effektor Zellzyklus Kontrollpunkt-proteinkinase Chk1, Materialien und Verfahren zur Identifizierung von Inhibitoren davon Expired - Fee Related DE60030229T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US460421 1990-01-03
US16288799P 1999-11-01 1999-11-01
US162887P 1999-11-01
US09/460,421 US6670167B1 (en) 1999-11-01 1999-12-14 Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof

Publications (2)

Publication Number Publication Date
DE60030229D1 true DE60030229D1 (de) 2006-10-05
DE60030229T2 DE60030229T2 (de) 2007-08-23

Family

ID=26859143

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60030229T Expired - Fee Related DE60030229T2 (de) 1999-11-01 2000-10-31 Katalytische Domäne der menschlichen Effektor Zellzyklus Kontrollpunkt-proteinkinase Chk1, Materialien und Verfahren zur Identifizierung von Inhibitoren davon

Country Status (9)

Country Link
US (2) US6670167B1 (de)
EP (1) EP1096014B1 (de)
JP (1) JP2001161387A (de)
KR (1) KR100431564B1 (de)
AT (1) ATE337401T1 (de)
AU (1) AU756175C (de)
CA (1) CA2325228C (de)
DE (1) DE60030229T2 (de)
ES (1) ES2270772T3 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670167B1 (en) * 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
GB0213186D0 (en) * 2002-06-08 2002-07-17 Univ Dundee Methods
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
EP1947102A1 (de) 2003-01-09 2008-07-23 Pfizer, Inc. Zusammensetzungen, enthaltend Diazepinoindol-Derivate als Kinase-Inhibitoren
US20050266469A1 (en) * 2004-05-25 2005-12-01 Raymond Christopher K Alternatively spliced isoforms of checkpoint kinase 1 (CHK1)
RU2442571C2 (ru) * 2004-07-23 2012-02-20 Дженентек, Инк. Кристаллизация антител или их фрагментов
JP5001167B2 (ja) * 2004-12-16 2012-08-15 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｒｈｏキナーゼ（ｒｏｋ）調節物質を同定するための、ハイスループット酵素免疫吸着アッセイ法（ｈｔ−ｅｌｉｓａ）
WO2009148896A2 (en) * 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
CN102156823B (zh) * 2011-02-18 2015-04-22 复旦大学 一种靶向作用于蛋白激酶非活性构象的化合物筛选方法
EP3024457A4 (de) 2013-07-26 2017-06-28 Update Pharma Inc. Zusammensetzungen zur verbesserung des therapeutischen nutzens von bisantren

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07109207B2 (ja) * 1990-10-18 1995-11-22 新キャタピラー三菱株式会社 負荷圧力補償型ロジック弁
AU4244793A (en) * 1992-05-12 1993-12-13 Arizona Board Of Regents On Behalf Of The University Of Arizona, The Human cell cycle checkpoint genes
US5595739A (en) 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
GB9518220D0 (en) * 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
WO1997018323A2 (en) 1995-11-16 1997-05-22 Icos Corporation Cell-cycle checkpoint phosphatidylinositol- (pik-) related kinases, genes coding therefor and methods for assaying and modulating enzymatic activity
US5714329A (en) 1995-11-29 1998-02-03 Sequana Theraputics, Inc. Methods for the diagnosis of a genetic predisposition to cancer associated with variant CDK4 allele
WO1997039143A2 (en) 1996-04-17 1997-10-23 Abbott Laboratories Methods for the identification of novel antifungal agents
GB9718952D0 (en) 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
ATE233325T1 (de) 1997-12-05 2003-03-15 Upjohn Co Fluoreszenz-basierte hts-(high throughput screening)assayverfahren für proteinkinase und phosphatase
US6021542A (en) * 1998-05-28 2000-02-08 Norman; Scott A. Self-cleaning hair brush
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
US6670167B1 (en) * 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
US20040005686A1 (en) * 2002-03-07 2004-01-08 Pharmacia Corporation Crystalline structure of human MAPKAP kinase-2

Also Published As

Publication number Publication date
ES2270772T3 (es) 2007-04-16
EP1096014B1 (de) 2006-08-23
KR100431564B1 (ko) 2004-05-22
DE60030229T2 (de) 2007-08-23
KR20010051660A (en) 2001-06-25
AU756175C (en) 2005-03-03
AU756175B2 (en) 2003-01-09
AU6807900A (en) 2001-05-10
US6670167B1 (en) 2003-12-30
JP2001161387A (ja) 2001-06-19
CA2325228A1 (en) 2001-05-11
ATE337401T1 (de) 2006-09-15
US20030235899A1 (en) 2003-12-25
EP1096014A2 (de) 2001-05-02
CA2325228C (en) 2004-08-17
EP1096014A3 (de) 2002-09-25

Similar Documents

Publication Publication Date Title
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
BG66094B1 (bg) Азабициклени съединения, тяхното получаване и използване като лекарствени средста, по-специално като антибактериални средства
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
BR0207811A (pt) Compostos de uréia aril e heteroaril substituìdos úteis no tratamento de doenças
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BR0016543A (pt) Novos derivados de piperidina e piperazina
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
DE60030229D1 (de) Katalytische Domäne der menschlichen Effektor Zellzyklus Kontrollpunkt-proteinkinase Chk1, Materialien und Verfahren zur Identifizierung von Inhibitoren davon
PT934309E (pt) Novas piridil-alcano-amidas como agentes citostaticos e imunossupressivos
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
BR0211863A (pt) 1-alquil ou 1-cicloalquiltriazolo[4,3a]quinazolin-5-onas como inibidores da fosfodiesterase
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
BR0308780A (pt) Composto, processo para a preparação e uso do mesmo, método para o tratamento de um sujeito humano ou animal que sofre de, ou que é suscetìvel a, uma condição inflamatória, e, composição farmacêutica
ATE332705T1 (de) Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen
BR0213417A (pt) Compostos e composições de tetraciclicazaindóis e indolinas tendo atividade de 5-ht e seus usos
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
BR0010693A (pt) Derivados azaindol para tratamento de depressão
UY26426A1 (es) Nuevos compuestos
ATE367160T1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee